VistaGen Awarded $3,700,000 NIH Drug Development Grant

VistaGen Therapeutics a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics for Central Nervous System (CNS) disorders and metabolic diseases using embryonic stem cell technologies, announced that the National Institute of Neurologic Disorders and Stroke (NINDS), a division of the U.S. National Institutes of Health (NIH), has awarded the company a $3,700,000 grant titled, "Preclinical Development of 4-Cl-KYN to Treat Epilepsy."

()a href="http://www.biospace.com/news_story.cfm?StoryID=20175720&full=1" target="_blank">BioSpace